3期临床-话题@MedSci

#3期临床#

90篇内容 | 2806人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1911223, encodeId=7ee0191122300, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, objectType=article, longId=87963, objectId=6f318e96342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f318e96342, replyNumber=0, likeNumber=80, createdTime=2017-08-18, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f318e96342, moduleTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f318e96342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911222, encodeId=d05319112223d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=糖尿病创新药sotagliflozin 3期临床试验获得成功, objectType=article, longId=85272, objectId=a907852e22a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a907852e22a, replyNumber=0, likeNumber=88, createdTime=2017-07-04, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a907852e22a, moduleTitle=糖尿病创新药sotagliflozin 3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a907852e22a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911220, encodeId=d350191122023, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状, objectType=article, longId=79164, objectId=59efe9164ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59efe9164ca, replyNumber=0, likeNumber=83, createdTime=2017-03-12, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59efe9164ca, moduleTitle=NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59efe9164ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911219, encodeId=8056191121955, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=3期临床结果优秀，可治疗“失明”的基因疗法或将上市, objectType=article, longId=75096, objectId=cecce509632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cecce509632, replyNumber=0, likeNumber=0, createdTime=2017-06-11, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cecce509632, moduleTitle=3期临床结果优秀，可治疗“失明”的基因疗法或将上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cecce509632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911216, encodeId=988019112161c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=NEJM：Eluxadoline 可安全有效的治疗腹泻型肠易激惹综合征（Eluxadoline 3期临床试验）, objectType=article, longId=62575, objectId=eada625e52a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eada625e52a, replyNumber=0, likeNumber=80, createdTime=2016-06-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eada625e52a, moduleTitle=NEJM：Eluxadoline 可安全有效的治疗腹泻型肠易激惹综合征（Eluxadoline 3期临床试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eada625e52a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911215, encodeId=da6419112153d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？, objectType=article, longId=41284, objectId=eb594128469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb594128469, replyNumber=0, likeNumber=75, createdTime=2014-11-21, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb594128469, moduleTitle=进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb594128469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911214, encodeId=fe35191121417, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=NEJM：3期临床试验证实中国手足口病疫苗安全有效, objectType=article, longId=31599, objectId=d5fa31599b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5fa31599b0, replyNumber=0, likeNumber=105, createdTime=2014-08-31, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5fa31599b0, moduleTitle=NEJM：3期临床试验证实中国手足口病疫苗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5fa31599b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911213, encodeId=c8ba191121306, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=ASCO 2013：二线治疗之Tivantinib的3期临床试验, objectType=article, longId=19771, objectId=9e6519e71bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e6519e71bd, replyNumber=0, likeNumber=68, createdTime=2013-09-13, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e6519e71bd, moduleTitle=ASCO 2013：二线治疗之Tivantinib的3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e6519e71bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911211, encodeId=42481911211b8, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=GreenGene F在美治疗A型血友病进入3期临床试验, objectType=article, longId=5397, objectId=fae7539ead, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fae7539ead, replyNumber=0, likeNumber=64, createdTime=2013-03-18, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fae7539ead, moduleTitle=GreenGene F在美治疗A型血友病进入3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fae7539ead)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911212, encodeId=aacc191121201, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Aeterna公司公布成人生长激素缺乏症治疗药物AEZS-130 3期临床结果, objectType=article, longId=7442, objectId=2e04e44244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e04e44244, replyNumber=0, likeNumber=88, createdTime=2012-09-08, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e04e44244, moduleTitle=Aeterna公司公布成人生长激素缺乏症治疗药物AEZS-130 3期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e04e44244)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期临床

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功

2017-08-18

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

糖尿病创新药sotagliflozin 3期临床试验获得成功

2017-07-04

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状

2017-03-12

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

3期临床结果优秀，可治疗“失明”的基因疗法或将上市

2017-06-11

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

NEJM：Eluxadoline 可安全有效的治疗腹泻型肠易激惹综合征（Eluxadoline 3期临床试验）

2016-06-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

进仿制版3期临床达到主要终点，阿达木单抗霸主地位受到威胁？

2014-11-21

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

NEJM：3期临床试验证实中国手足口病疫苗安全有效

2014-08-31

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

ASCO 2013：二线治疗之Tivantinib的3期临床试验

2013-09-13

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

GreenGene F在美治疗A型血友病进入3期临床试验

2013-03-18

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Aeterna公司公布成人生长激素缺乏症治疗药物AEZS-130 3期临床结果

2012-09-08

科室
- - 订阅+
  - 更多科室
工具
服务